Becherel O J, Fuchs R P
UPR 9003 du Centre National de la Recherche Scientifique, Unité Propre de Recherche du CNRS conventionnée avec l'Université de Strasbourg, Institut de Recherche sur les Cancers de l'Appareil Digestif, Strasbourg, France.
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8566-71. doi: 10.1073/pnas.141113398. Epub 2001 Jul 10.
Escherichia coli possesses three SOS-inducible DNA polymerases (Pol II, IV, and V) that were recently found to participate in translesion synthesis and mutagenesis. Involvement of these polymerases appears to depend on the nature of the lesion and its local sequence context, as illustrated by the bypass of a single N-2-acetylaminofluorene adduct within the NarI mutation hot spot. Indeed, error-free bypass requires Pol V (umuDC), whereas mutagenic (-2 frameshift) bypass depends on Pol II (polB). In this paper, we show that purified DNA Pol II is able in vitro to generate the -2 frameshift bypass product observed in vivo at the NarI sites. Although the Delta polB strain is completely defective in this mutation pathway, introduction of the polB gene on a low copy number plasmid restores the -2 frameshift pathway. In fact, modification of the relative copy number of polB versus umuDC genes results in a corresponding modification in the use of the frameshift versus error-free translesion pathways, suggesting a direct competition between Pol II and V for the bypass of the same lesion. Whether such a polymerase competition model for translesion synthesis will prove to be generally applicable remains to be confirmed.
大肠杆菌拥有三种SOS诱导型DNA聚合酶(Pol II、IV和V),最近发现它们参与跨损伤合成和诱变。这些聚合酶的参与似乎取决于损伤的性质及其局部序列背景,如在NarI突变热点内单个N-2-乙酰氨基芴加合物的跨越所示。实际上,无错误跨越需要Pol V(umuDC),而诱变(-2移码)跨越则依赖于Pol II(polB)。在本文中,我们表明纯化的DNA Pol II在体外能够产生在体内NarI位点观察到的-2移码跨越产物。尽管Delta polB菌株在该突变途径中完全缺陷,但在低拷贝数质粒上引入polB基因可恢复-2移码途径。事实上,polB与umuDC基因相对拷贝数的改变会导致移码与无错误跨损伤途径使用的相应改变,这表明Pol II和V在跨越同一损伤时存在直接竞争。这种跨损伤合成的聚合酶竞争模型是否普遍适用仍有待证实。